Disclosed CapitolDisclosedCapitol
Home
Plans
Chad AI
API
Sign InGet Pro

Never Miss a Trade

Get weekly trade alerts free.

Explore

  • Politician Trades
  • Politicians
  • Executive Branch
  • Companies
  • All Stocks A–Z
  • Leaderboard
  • Compare Politicians
  • Committee Portfolios
  • Chad AI

Money & Policy

  • Government Contracts
  • Lobbying
  • Legislation
  • Campaign Finance
  • Institutional (13F)
  • Whale Watch (13D)

Markets

  • Markets Overview
  • Top Companies
  • Insider Trends
  • Economic Indicators
  • Live News

Resources

  • API Access
  • Developers
  • Data Export
  • Glossary
  • Methodology
  • Data Sources
  • How It Works

Company

  • About Us
  • Press
  • FAQ
  • Pricing
  • vs. Capitol Trades
  • Contact
  • Watchlist

Legal

  • Editorial Standards
  • Corrections
  • Disclaimers
  • Privacy
  • Terms
© 2026 Disclosed Capitol. All rights reserved.
TermsPrivacyDisclaimer
HomeTrades
Chad
WatchlistAccount

BLFS

Healthcare
BioLife Solutions, Inc. · Medical Instruments & Supplies
Trades
6
Politicians
0
Buys
2
Sells
2
Trades
6
Politicians
0
Buys
2
Sells
2
BLFSvs S&P 500 (normalized)
|to
No price data available
BLFS S&P 500 Buy Sell
Range
PoliticianActionDescriptionAmountTradedFiled
Michael McCaulR
SellBURLINGTON STORES INC$1K - $15KMay 2, 2023Jun 6, 2023
Christopher L. JacobsR
SellBioLife Solutions, Inc.$1K - $15KDec 12, 2022Jan 10, 2023
Christopher L. JacobsR
BuyBioLife Solutions, Inc.$1K - $15KNov 8, 2022Dec 7, 2022
Tom MalinowskiD
BuyBiolife Solutions, Inc.$1K - $15KJul 7, 2020Aug 1, 2020
Tom MalinowskiD
BuyBioLife Solutions Inc NEW$1K - $15KDec 8, 2019Jan 7, 2020
Ro KhannaD
BuyBIOLIFE SOLUTIONS INC CMN$1K - $15KFeb 27, 2018Mar 5, 2018

BioLife Solutions, Inc. (BLFS) Congressional Stock Trades

This page tracks congressional stock trading activity in BioLife Solutions, Inc. (BLFS) in the Healthcare sector. Disclosed Capitol has indexed 6 disclosed congressional trades involving BLFS. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.

As of June 2023 — Disclosed Capitol has tracked 6 disclosed congressional trades in BioLife Solutions, Inc. (BLFS) — 2:2 buy-heavy ratio — led by Christopher L. Jacobs (R).

Which members of Congress trade BioLife Solutions, Inc.?

  • Christopher L. Jacobs (R) — 2 disclosed trades in BLFS
  • Tom Malinowski (D) — 2 disclosed trades in BLFS
  • Michael McCaul (R) — 1 disclosed trade in BLFS
  • Ro Khanna (D) — 1 disclosed trade in BLFS

Recent BLFS congressional trades

DatePoliticianPartyActionAmount
May 2, 2023Michael McCaulRSale$1,001 - $15,000
Dec 12, 2022Christopher L. JacobsRSale$1,001 - $15,000
Nov 8, 2022Christopher L. JacobsRBuy$1,001 - $15,000
Jul 7, 2020Tom MalinowskiDBuy$1,001 - $15,000
Dec 8, 2019Tom MalinowskiDPurchase$1,001 - $15,000
Feb 27, 2018Ro KhannaDPurchase$1,001 - $15,000

Buy vs. sell ratio & volume

Across the 6 disclosed congressional trades in BioLife Solutions, Inc. (BLFS), members of Congress have reported 2 buys and 2 sells. The average 30-day alpha vs. the S&P 500 is 9.68%.

Does BioLife Solutions, Inc. receive U.S. government contracts?

As of July 2022, BioLife Solutions, Inc. has 1 federal contract award record on file from USAspending.gov — most recently $150K from the Department of Health and Human Services on 2022-07-27.

Award dateAgencyAmount
2022-07-27Department of Health and Human Services · National Institutes of Health$150K

Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.

BioLife Solutions, Inc. financial snapshot (FY2025)

For fiscal year 2025, BioLife Solutions, Inc. reported revenue of $143.3M and net income of -$66.4M, per SEC filings.

Revenue
$143.3M
Gross profit
$41.3M
Operating income
-$70.8M
Net income
-$66.4M
Diluted EPS
$-1.52
Gross margin
28.8%
Net margin
-46.4%
Free cash flow
-$18.9M

Most recent reported quarter: Q2 FY2026 — revenue $28.5M, net income $45.1M.

Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.